Mandolesi, Marco http://orcid.org/0000-0003-2927-7831
Das, Hrishikesh http://orcid.org/0000-0001-7495-7065
de Vries, Liset http://orcid.org/0000-0002-4797-086X
Yang, Yiqiu
Kim, Changil
Dhinakaran, Manojj http://orcid.org/0000-0003-2536-8699
Castro Dopico, Xaquin http://orcid.org/0000-0002-9005-6774
Fischbach, Julian http://orcid.org/0000-0001-9411-9181
Kim, Sungyong
Guryleva, Mariia V.
Àdori, Monika
Chernyshev, Mark http://orcid.org/0000-0003-1622-9240
Stålmarck, Aron
Hanke, Leo http://orcid.org/0000-0001-5514-2418
McInerney, Gerald M. http://orcid.org/0000-0003-2257-7241
Sheward, Daniel J. http://orcid.org/0000-0002-0227-5636
Corcoran, Martin
Hällberg, B. Martin http://orcid.org/0000-0002-6781-0345
Murrell, Ben http://orcid.org/0000-0002-0393-4445
Karlsson Hedestam, Gunilla B. http://orcid.org/0000-0001-7255-9047
Funding for this research was provided by:
Svenska Forskningsrådet Formas (2018-05973, 2018-02381, 2017-00968, 2017-6702, 2018-3808, 2022-06725, 2017-00968, 2017-6702, 2018-3808)
EC | Horizon 2020 Framework Programme (101003653, 101003653)
Science for Life Laboratory (VC-2022-0028, VC-2022-0028)
Familjen Erling-Perssons Stiftelse (20210125, 20210125)
Knut och Alice Wallenbergs Stiftelse
Article History
Received: 15 February 2024
Accepted: 3 July 2024
First Online: 27 July 2024
Competing interests
: D.J.S. consults for AstraZeneca AB on matters related to monoclonal antibody therapeutics for Covid-19. The remaining authors declare no competing interests.